<a href="https://www.fiercebiotech.com/biotech/passage-launches-strategic-review-and-75-layoffs-after-gene-therapy-path-blocked-fda" hreflang="en">Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA</a>
Passage Bio is undergoing a strategic review and plans to lay off 75% of its workforce after the FDA blocked its lead gene therapy candidate, PBFT02, from proceeding with a single-arm trial. The company aims to evaluate potential next steps, including a merger or sale, in light of the regulatory challenges and associated costs.
For a professional tracking healthtech and biotech, the key insight here is the significant impact of FDA's regulatory stance on single-arm trials for gene therapies, as demonstrated by Passage Bio's strategic review and workforce reduction. This highlights the critical need for biotech companies to align clinical trial designs with FDA expectations to avoid costly setbacks, making it essential for stakeholders to closely monitor regulatory trends and guidelines to mitigate risks in drug development and approval processes.